Akebia Therapeutics, Inc. (AKBA) financial statements and ratios from SEC XBRL: revenue $236.20M (TTM), net margin -2.3%, revenue growth 47.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $236.20M |
| Net Margin | -2.3% |
| Revenue Growth (YoY) | 47.5% |
| EPS Growth (YoY) | -93.9% |
| FCF Growth (YoY) | -266.4% |
| Price / Book | 9.74 |
| Price / Sales | 1.13 |
| FCF Yield | -10.1% |
| DCF Value (model) | $0.06 |
| DCF Upside vs Price | -93.4% |
| Altman Z-Score | -4.72 (distress) |
| Piotroski F-Score | 6/9 |
| Sector P/E (Healthcare) | 21.7 |
AKBA overview · AKBA earnings · AKBA KPIs · AKBA investor relations · AKBA ownership · AKBA peers · AKBA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.